HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target

Benzinga · 03/11 17:03
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.